[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Identifieur interne : 000D66 ( Main/Corpus ); précédent : 000D65; suivant : 000D67[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Auteurs : E. Díaz ; R. Amézaga Menéndez ; P. Vidal Cortés ; M G Escapa ; B. Suberviola ; A. Serrano Lázaro ; P. Marcos Neira ; M. Quintana Díaz ; M. Catalán GonzálezSource :
- Medicina intensiva [ 1578-6749 ] ; 2021.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Adrenal Cortex Hormones (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (drug therapy), COVID-19 (therapy), Disease Progression (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Immunoglobulins, Intravenous (therapeutic use), Immunomodulation (MeSH), Interferon-beta (therapeutic use), Interleukin 1 Receptor Antagonist Protein (therapeutic use), Lopinavir (therapeutic use), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (therapeutic use), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Adrenal Cortex Hormones, Alanine, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Anticoagulants, Antiviral Agents, Azithromycin, Hydroxychloroquine, Immunoglobulins, Intravenous, Interferon-beta, Interleukin 1 Receptor Antagonist Protein, Lopinavir, Protein Kinase Inhibitors, Pyrazoles, Ritonavir.
- drug therapy : COVID-19.
- therapy : COVID-19.
- Disease Progression, Humans, Immunization, Passive, Immunomodulation, SARS-CoV-2.
Abstract
Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.
DOI: 10.1016/j.medin.2020.06.017
PubMed: 32854988
PubMed Central: PMC7833076
Links to Exploration step
pubmed:32854988Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].</title><author><name sortKey="Diaz, E" sort="Diaz, E" uniqKey="Diaz E" first="E" last="Díaz">E. Díaz</name><affiliation><nlm:affiliation>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona, España. Electronic address: emilio.diaz.santos@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Amezaga Menendez, R" sort="Amezaga Menendez, R" uniqKey="Amezaga Menendez R" first="R" last="Amézaga Menéndez">R. Amézaga Menéndez</name><affiliation><nlm:affiliation>Hospital Universitari Son Espases, Palma, España.</nlm:affiliation></affiliation></author><author><name sortKey="Vidal Cortes, P" sort="Vidal Cortes, P" uniqKey="Vidal Cortes P" first="P" last="Vidal Cortés">P. Vidal Cortés</name><affiliation><nlm:affiliation>Complexo Hospitalario Universitario Ourense, Ourense, España.</nlm:affiliation></affiliation></author><author><name sortKey="Escapa, M G" sort="Escapa, M G" uniqKey="Escapa M" first="M G" last="Escapa">M G Escapa</name><affiliation><nlm:affiliation>Hospital Universitario de Burgos, Burgos, España.</nlm:affiliation></affiliation></author><author><name sortKey="Suberviola, B" sort="Suberviola, B" uniqKey="Suberviola B" first="B" last="Suberviola">B. Suberviola</name><affiliation><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, España.</nlm:affiliation></affiliation></author><author><name sortKey="Serrano Lazaro, A" sort="Serrano Lazaro, A" uniqKey="Serrano Lazaro A" first="A" last="Serrano Lázaro">A. Serrano Lázaro</name><affiliation><nlm:affiliation>Hospital Clínico Universitario de Valencia, Valencia, España.</nlm:affiliation></affiliation></author><author><name sortKey="Marcos Neira, P" sort="Marcos Neira, P" uniqKey="Marcos Neira P" first="P" last="Marcos Neira">P. Marcos Neira</name><affiliation><nlm:affiliation>Hospital Germans Trias y Pujol, Badalona, España.</nlm:affiliation></affiliation></author><author><name sortKey="Quintana Diaz, M" sort="Quintana Diaz, M" uniqKey="Quintana Diaz M" first="M" last="Quintana Díaz">M. Quintana Díaz</name><affiliation><nlm:affiliation>Hospital Universitario La Paz, Madrid, España.</nlm:affiliation></affiliation></author><author><name sortKey="Catalan Gonzalez, M" sort="Catalan Gonzalez, M" uniqKey="Catalan Gonzalez M" first="M" last="Catalán González">M. Catalán González</name><affiliation><nlm:affiliation>Hospital Universitario 12 de Octubre, Madrid, España.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32854988</idno><idno type="pmid">32854988</idno><idno type="doi">10.1016/j.medin.2020.06.017</idno><idno type="pmc">PMC7833076</idno><idno type="wicri:Area/Main/Corpus">000D66</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].</title><author><name sortKey="Diaz, E" sort="Diaz, E" uniqKey="Diaz E" first="E" last="Díaz">E. Díaz</name><affiliation><nlm:affiliation>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona, España. Electronic address: emilio.diaz.santos@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Amezaga Menendez, R" sort="Amezaga Menendez, R" uniqKey="Amezaga Menendez R" first="R" last="Amézaga Menéndez">R. Amézaga Menéndez</name><affiliation><nlm:affiliation>Hospital Universitari Son Espases, Palma, España.</nlm:affiliation></affiliation></author><author><name sortKey="Vidal Cortes, P" sort="Vidal Cortes, P" uniqKey="Vidal Cortes P" first="P" last="Vidal Cortés">P. Vidal Cortés</name><affiliation><nlm:affiliation>Complexo Hospitalario Universitario Ourense, Ourense, España.</nlm:affiliation></affiliation></author><author><name sortKey="Escapa, M G" sort="Escapa, M G" uniqKey="Escapa M" first="M G" last="Escapa">M G Escapa</name><affiliation><nlm:affiliation>Hospital Universitario de Burgos, Burgos, España.</nlm:affiliation></affiliation></author><author><name sortKey="Suberviola, B" sort="Suberviola, B" uniqKey="Suberviola B" first="B" last="Suberviola">B. Suberviola</name><affiliation><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, España.</nlm:affiliation></affiliation></author><author><name sortKey="Serrano Lazaro, A" sort="Serrano Lazaro, A" uniqKey="Serrano Lazaro A" first="A" last="Serrano Lázaro">A. Serrano Lázaro</name><affiliation><nlm:affiliation>Hospital Clínico Universitario de Valencia, Valencia, España.</nlm:affiliation></affiliation></author><author><name sortKey="Marcos Neira, P" sort="Marcos Neira, P" uniqKey="Marcos Neira P" first="P" last="Marcos Neira">P. Marcos Neira</name><affiliation><nlm:affiliation>Hospital Germans Trias y Pujol, Badalona, España.</nlm:affiliation></affiliation></author><author><name sortKey="Quintana Diaz, M" sort="Quintana Diaz, M" uniqKey="Quintana Diaz M" first="M" last="Quintana Díaz">M. Quintana Díaz</name><affiliation><nlm:affiliation>Hospital Universitario La Paz, Madrid, España.</nlm:affiliation></affiliation></author><author><name sortKey="Catalan Gonzalez, M" sort="Catalan Gonzalez, M" uniqKey="Catalan Gonzalez M" first="M" last="Catalán González">M. Catalán González</name><affiliation><nlm:affiliation>Hospital Universitario 12 de Octubre, Madrid, España.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Medicina intensiva</title><idno type="eISSN">1578-6749</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (therapy)</term><term>Disease Progression (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunization, Passive (MeSH)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Immunomodulation (MeSH)</term><term>Interferon-beta (therapeutic use)</term><term>Interleukin 1 Receptor Antagonist Protein (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (therapeutic use)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Adrenal Cortex Hormones</term><term>Alanine</term><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Anticoagulants</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term><term>Immunoglobulins, Intravenous</term><term>Interferon-beta</term><term>Interleukin 1 Receptor Antagonist Protein</term><term>Lopinavir</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term><term>Immunization, Passive</term><term>Immunomodulation</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32854988</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-6749</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>03</Month></PubDate></JournalIssue><Title>Medicina intensiva</Title><ISOAbbreviation>Med Intensiva</ISOAbbreviation></Journal><ArticleTitle>[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].</ArticleTitle><Pagination><MedlinePgn>104-121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0210-5691(20)30247-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medin.2020.06.017</ELocationID><Abstract><AbstractText>Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Área de Críticos, Corporación Sanitaria i Universitaria Parc Taulí, Univ. Autonoma de Barcelona, CIBER de Enfermedades Respiratorias, Sabadell, Barcelona, España. Electronic address: emilio.diaz.santos@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amézaga Menéndez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Universitari Son Espases, Palma, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal Cortés</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Complexo Hospitalario Universitario Ourense, Ourense, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escapa</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Burgos, Burgos, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suberviola</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hospital Universitario Marqués de Valdecilla, Santander, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano Lázaro</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Clínico Universitario de Valencia, Valencia, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos Neira</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital Germans Trias y Pujol, Badalona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana Díaz</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario La Paz, Madrid, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalán González</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Madrid, España.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH).</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Intensiva</MedlineTA><NlmUniqueID>9207689</NlmUniqueID><ISSNLinking>0210-5691</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540383">INCB018424</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>T4H8FMA7IM</RegistryNumber><NameOfSubstance UI="C504234">siltuximab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ARDS-CoV-2</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">ICU</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">Tratamiento</Keyword><Keyword MajorTopicYN="Y">Treatment</Keyword><Keyword MajorTopicYN="Y">UCI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32854988</ArticleId><ArticleId IdType="pii">S0210-5691(20)30247-3</ArticleId><ArticleId IdType="doi">10.1016/j.medin.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7833076</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32854988
|texte= [Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32854988" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |